Discover 1 curated intelligence briefings related to this specific topic.
The pharmaceutical industry has a blind spot. We celebrate the discovery of new molecules but ignore the brutal economics of downstream processing, where recovery costs and material instability turn laboratory breakthroughs into commercial failures.
